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Alport syndrome (ATS) and benign familial hematuria (BFH)
are type IV collagen inherited disorders. Mutations in COL4A5
are generally believed to cause X-linked ATS, whereas
mutations in COL4A3 and COL4A4 genes can be associated
with the autosomal-recessive and -dominant type of ATS or
BFH. In view of the wide spectrum of phenotypes, an exact
diagnosis is sometimes difficult to achieve. This study
involved screening each exon with boundary intronic
sequences of COL4A3, COL4A4, and COL4A5 genes by
optimized polymerase chain reaction-single-stranded
conformational polymorphism analysis in 17 families with
ATS and in 40 families diagnosed as having BFH. Twelve
different mutations were found in the COL4A5 gene in ATS
patients, comprising nine missense mutations, a splice site
mutation, a mutation causing frameshift, and a nonsense
mutation. One of the missense mutations (p.G624D) was
present not only in one family with ATS but also in five
families with suspected BFH. Three heterozygous mutations
in the COL4A3 gene (two missense and one frameshift) and
four heterozygous mutations in COL4A4 (two splice site, one
in-frame deletion, and one missense) were identified in
patients with BFH. Sixteen mutations are to the best of our
knowledge new and private.
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Thin basement membrane nephropathy is the most common
diagnosis in patients with persistent benign familial hema-
turia (BFH) (OMIM 141200) of glomerular origin and it
probably affects at least 1% of population. The condition is
characterized by prominent diffuse thinning of the glomer-
ular basement membrane (GBM) on an ultrastructural level,
lifelong glomerular hematuria, which may be accompanied
by mild proteinuria, normal renal function, and an
autosomal-dominant inheritance pattern.1,2 Alport syndrome
(ATS) (OMIM 301050) is another inherited disorder affecting
basement membranes and is manifested by hematuria with
varying degrees of proteinuria, progressive nephritis with
declining renal function, progressive sensorineural deafness,
and ocular abnormalities. The most common form of ATS is
dominant, X chromosome linked (85%). Female carriers have
a variable and generally milder clinical course of the disease.
In 95% of male patients, the disease is characterized by end-
stage renal failure. Electron microscopy examination of
kidney biopsy samples demonstrates characteristic abnorma-
lities of the GBM, expressed as irregular thinning, as well as a
diagnostic, more or less widespread thickening of the GBM
with splitting and fragmentation of the lamina densa into
several strands, forming a ‘basket-weave’ pattern.3 ATS linked
on chromosome X is caused by mutations in the COL4A5
gene (Xq22), which codes for the a5 chain of collagen IV, a
major structural component of GBM.4 To date, more than
300 mutations have been identified in COL4A5, which appear
randomly along the gene.5 The autosomal forms of ATS,
present in 15% of patients, are caused by mutations in
COL4A3 and COL4A4 genes, which are located on chromo-
some 2 and code for a3 and a4 chains of collagen IV.6
Mutations in COL4A3 and COL4A4 genes have also been
reported in the autosomal-dominant form of ATS and BFH,
and it has been suggested that thin basement membrane
disease represents a carrier state of autosomal-recessive
ATS.7–11
Exact diagnosis can be a difficult clinical task, particularly
in children and females, when persistent hematuria and
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electron microscopic attenuation of the GBM are the only
findings and thin basement membrane disease cannot be
clinically distinguished from the initial stage of ATS.
Molecular analysis of type IV collagen genes could thus
provide information essential for diagnosis, prenatal diag-
nosis, and genetic counselling.8
The aim of this study was the screening of 52, 47, and 51
exons with boundary intronic sequences of COL4A3,
COL4A4, and COL4A5 genes, respectively, by single-stranded
conformational polymorphism (SSCP) analysis in 17 ATS
families and in 40 families diagnosed with BFH, in order to
determine potentially pathogenic mutations in collagen genes
and thus to contribute to precise diagnosis, as well as to
correlate molecular genetic findings with the main clinical
features.
RESULTS
Polymerase chain reaction (PCR)-SCCP analysis of all exons
of the COL4A3, COL4A4, and COL4A5 genes from 17
families diagnosed with ATS and in 40 families diagnosed
with BFH showed the presence of 17 pathogenic mutations in
the COL4A5 gene, three in the COL4A3 gene, and four in the
COL4A4 gene. The frequency of COL4A5 mutations was thus
12/17 (70.6%) in ATS families and 5/40 (12.5%) in BFH
families, whereas the frequencies of COL4A3 and COL4A4
mutations were 3/40 (7.5%) and 4/40 (10.0%), respectively,
in BFH families. Four rare variants of unknown pathogenesis
and 19 polymorphisms were found in the COL4A3 and
COL4A4 genes.
COL4A5
Mutations identified in COL4A5 are presented in Table 1a.
There were 12 different mutations found in 17 families (one
mutation detected in six different families), of which 10 are
new. None of these mutations was found in the control group
of 137 healthy blood donors.
A nonsense mutation was identified in an ATS male
patient from the family XXXIV. A change from C4T of the
first base of codon 266 in exon 15 leads to premature stop
codon. In a male patient diagnosed with ATS from family XI,
a deletion 3615_3616delC in exon 38 caused a frameshift,
which 14 codons further on resulted in a stop codon. A splice
site mutation 1234þ 5G4T in intron 18 was demonstrated
in a mother and two sons from the ATS family XXIV.
Nine different missense mutations were found in our
patients and all of them were glycine substitutions, eight of
them found in sequences coding for Gly-X-Y repeats of the
collagenous domain and one in the non-collagenous domain
(p.G624D). Glycine was changed to aspartic acid (p.G319D,
p.G624D, p.G666D), glutamic acid (p.G198E, p.G466E), or
arginine (p.G310R, p.G325R, p.G669R, and p.G811R). All of
the glycine substitutions, except p.G624D, were found in ATS
families only. The mutation p.G624D was found in six
unrelated families: in a 45-year-old female patient from
family XIV with a diagnosis of ATS, in a mother and son
from family XVI, and a father and two daughters from family
XLII with BFH and diffuse thinning of the GBM on
ultrastructural examination, as well as in families XXXIII,
XXXVI, and XLVIII with clinical presentation of BFH, but no
kidney biopsy performed.
The non-glycine substitution p.K664N was found in a
mother and two daughters, but not in the grandmother from
family XXXVIII, all suspected as having ATS (Table 1b). No
other mutation was identified in patients from this family.
Four silent mutations (p.G365G, p.P738P, p.Q1171Q,
p.D1425D) and missense mutation p.I444S, as sequence
variants, were identified in a healthy mother and her son with
hematuria of family IX. In the son, we also detected a
mutation in the COL4A4 gene (Table 2).
COL4A4
Two splice site mutations, one frameshift mutation, one
missense mutation, four rare variants, and 11 polymor-
phisms, detected in the COL4A4 gene, are presented in Tables
2–4. All mutations are in a heterozygous state, private,
previously undescribed and were found in family members
with persistent benign microhematuria or proven thin
basement membrane disease.
A splice site mutation (c.2860þ 2T4G) in intron 31 was
found in a mother and son from family XXXI with persistent
benign hematuria. Electron microscopy examination of the
renal biopsy performed in the 41-year-old mother showed
prominent thinning of the GBM. A father and daughter from
family XL, both with hematuria but no renal biopsy
performed, had a splice site mutation (c.3289þ 1G4A) in
intron 35. Nucleotide substitution (G to C) at position 3145
and a further deletion of five nucleotides (c.3145-3150de-
linsC), found in a father and son from family IX with a
diagnosis of BFH, resulted in a shift of a reading frame.
A missense mutation p.G774R was found in two sisters and
their two sons from family LV, all of them affected with
benign persistent hematuria. Renal biopsy was performed in
two members of the family and diffuse thinning of GBM was
demonstrated.
We identified four more variants of no clear pathogenic
significance. In family XII, a nucleotide change c.4082-
8G4C was found only in three children with hematuria, but
not in the father, who also had hematuria. We detected
another nucleotide change (c.3506-8T4G) in intron 37 in a
father and daughter from family XXIX. A non-glycine
substitution p.R908W, occurring in the third position in
-Gly-X-Y- repeats in the collagenous domain, was detected
only in a daughter but not in the father, both with hematuria
from family XXVIII. A silent mutation p.G789G was found in
two affected members of family XXI. All four mutations and
variants were absent in the control group.
Furthermore, we found 11 polymorphisms that were also
found in the control group. Nine of them have already been
described in the literature, whereas we characterized two of
them, c.2165-27insA and p.S1102S, as novel polymorphisms
with low allele frequency. The frequencies in controls are
presented in Table 4.
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Table 1a | Mutations in COL4A5 gene identified in 44 patients of 17 families
Family Mutationsa Nucleotide change Exon Gender
Age at
study
Nonsense
XXXIV/II-1 p.R226X c.998C4T 14 M 30
Frameshift
XI/II-1 c.3615_3616del C c.3615_3616del C 38 M 34
Splicing
XXIV/I-1 c.1234+5 G4T c.1234+5 G4T 18 F 47
XXIV/II-1 M 24
XXIV/II-2 M 24
Missense
XXII/II-1 p.G198E c.795G4A 10 F 28
XXII/III-1 M 5
VIII/II-1 p.G310R c.1130G4A 16 F 35
VIII/III-1 F 6
LIV/II-1 p.G319D c.1158 G4A 17 F 60
LIV/II-2 F 56
LIV/II-3 F 52
LIV/II-4 F 49
LIV/II-5 M 44
LIV/II-6 F 44
LIV/III-1 F 29
LIV/III-2 F 26
LIV/III-3 M 26
LIV/IV-1 M 4
XIX/II-1 p.G325R c.1175G4C 17 M 27
LVI/I-1 p.G466E c.1599G4A 21 M 39
LVI/II-1 F 15
XIV p.G624D c.2073G4A 25 F 47
XVI/II-1 p.G624D c.2073G4A 25 M 20
XXXIII/II-1 p.G624D c.2073G4A 25 F 22
XXXIII/II-2 F 16
XXXVI/I-1 p.G624D c.2073G4A 25 F 39
XXXVI/II-1 M 15
XLII/I-1 p.G624D c.2073G4A 25 M 42
XLII/II-1 F 16
XLII/II-2 F 14
XLVIII/I-1 p.G624D c.2073G4A 25 M 46
XLVIII/II-1 F 16
XLVIII/II-2 F 14
III/II-1 p.G669R c.2207G4C 26 F 35
III/II-2 F 39
III/III-1 M 24
III/III-2 M 7
III/IV-1 F 3
LVII/II-1 p.G666D c.2199G4A 26 F 37
LVII/III-1 M 12
LVII/III-2 M 2
LI/II-1 p.G811R c.2633C4A 30 M 41
LI/II-2 M 35
Clinical data at study EM GBM changes
Hematuria Proteinuria
Renal function
findings
Patient age at
renal biopsy Thinning
Splitting/
thickening
Hearing
loss
Ocular
lesions
Yes Yes ESRD at 24 7 Yes Yes Yes No
Yes Yes ESRD at 20 13 Yes Yes Yes No
Yes Yes ESRD at 36 — — — No No
Yes Yes CRF 23 Yes Yes No Yes
Yes Yes CRF — — — No No
Yes No Normal 5 Yes Yes No No
Yes Yes Normal — — — Yes Yes
Yes Yes Normal 13 Yes Yes No No
Table 1a continued on the following page
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COL4A3
We detected two missense mutations and an insertion of
three nucleotides in COL4A3 gene in patients with BFH
(Table 5). A glycine substitution (p.G487C), found in a father
and daughter from family XXXII, was a private and new
mutation, whereas another glycine substitution (p.G1015E)
detected in family XVII has already been described. In family
IV, we identified a three-nucleotide insertion (c.3547_3548in-
sGGA), causing the insertion of another glycine residue
at the first position of -Gly-X-Y- repeats in the collagenous
domain. Finally, nine polymorphisms were identified,
all of them previously reported in other populations
(Table 6).
DISCUSSION
Because of the clinical variability of ATS and similarities
between BFH and ATS, particularly during the initial course,
the demonstration of genetic mutations is an important non-
invasive method for a precise final diagnosis. In this study, we
analyzed all exons and their intronic boundaries of genes
COL4A3, COL4A4, and COL4A5, in 17 families with ATS and
in 40 families with a clinical diagnosis of BFH.
We found pathogenic mutations in gene COL4A5 in 71%
(12/17) of ATS families and in 13% (5/40) of families with a
diagnosis of BFH. Our results in ATS families are in line with
other studies of COL4A5 using SSCP.12–17 Ten of the 12
identified mutations in gene COL4A5 are to the best of our
Yes No Normal — — No No
Yes Yes CRF — — — Yes Yes
Yes Yes Normal 34 Yes Yes No Yes
Yes Yes Normal 29 Yes Yes Yes Yes
Yes Yes Normal 27 Yes Yes Yes Yes
Yes Yes ESRD at 25 20 No Yes Yes Yes
Yes Yes CRF 22 Yes Yes No Yes
Yes Yes Normal 10 Yes Yes Yes No
Yes Yes Normal 13 Yes Yes No No
Yes Yes CRF 8 Yes Yes Yes No
Yes No Normal — — — No Yes
Yes Yes CRF 8 Yes Yes No No
Yes Yes ESRD at 38 9 Yes Yes Yes No
Yes No Normal — — — No No
Yes Yes Normal 46 Yes Yes No Yes
Yes No Normal 16 Yes No No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal 15 Yes No No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes No Normal — — — No No
Yes Yes Normal 5 Yes Yes No No
Yes Yes ESRD at 23 — — — No No
Yes Yes ESRD at 18 17 Yes Yes Yes Yes
Yes Yes Normal — — — No Yes
Yes No Normal — — — No Yes
Yes Yes Normal 7 Yes Yes Yes No
Yes Yes Normal — — — Yes No
Yes Yes Normal — — — No No
Yes Yes ESRD at 28 — — — Yes Yes
Yes Yes ESRD at 26 11 Yes Yes Yes Yes
CRF, cronic renal failure; F, female; GBM, glomerular basement membrane; EM, electron microscopy; ESRD, end-stage renal disease; M, male.
aPreviously undescribed mutations are shown in bold type.
Table 1a | Continued
Clinical data at study EM GBM changes
Hematuria Proteinuria
Renal function
findings
Patient age at
renal biopsy Thinning
Splitting/
thickening
Hearing
loss
Ocular
lesions
Table 1b | Mutations in COL4A5 gene which do not cause
Alport syndrome
Family Mutations Nucleotide change Exon
IX G365G G4C at 1297 19
I444S T4G at 1533 20
P783P G4A at 2551 29
Q1171Q A4G at 3715 39
D1425D C4T at 4486 46
XXXVIII K664N G4T at 21944 26
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knowledge new. All mutations are very likely pathogenically
important because of their absence in 137 controls.
According to the literature, most families with ATS have
different and unique mutations.3 However, Barker et al.18
reported a shared mutation p.L1649R in nine families from
the United States with X-linked ATS due to a founder effect.
Similarly, we found a missense mutation p.G624D in gene
COL4A5, in six unrelated families (Table 1a). This glycine
substitution in the non-collagenous domain has already been
previously reported in two different families with ATS, one in
a study that included patients from Denmark, Germany,
Iceland, Sweden, and United States19 and the other in a study
including patients from the United States.20 In our study, this
mutation was demonstrated in a 47-year-old female patient
with a diagnosis of ATS confirmed by electron microscopy of
the kidney biopsy. Her brother had end-stage renal failure at
the age of 45 years. Furthermore, the same mutation was also
found in five families (XVI, XXXIII, XXXVI, XLII, and
XLVIII) with a clinical picture of BFH. However, the finding
of thin basement membrane by electron microscopy in a 16-
year-old member of family XVI is not a convincing
confirmation of the benign nature of the disease. Conversely,
isolated hematuria with normal renal function in two male
patients at the age of 42 and 46 years, respectively, of families
XLII and XLVIII, seem to be important arguments in favor of
BFH associated with COL4A5 mutation. It is generally
believed that mutations of gene COL4A5 cause ATS, which
may vary in the severity of clinical manifestations and
progression of renal disease in relation to the type of
mutation. However, our finding of the missense mutation
p.G624D of COL4A5 in a family with a progressive form of
ATS, as well as in families affected with BFH suggests the
possibility of significantly different phenotypes associated
with the same gene mutation. It could be speculated that
members of the five families are affected with a very mild
form of ATS, but we are more prone to the hypothesis that
ATS and BFH may represent two opposite poles of the
spectrum of hereditary COL4A5 nephropathies, similar to
hereditary nephropathies associated with COL4A3 and
COL4A4 heterozygous mutations. This is a quite new
observation of our study and further medical surveillance
of these families will probably contribute to clarification of
this dilemma.
All other missense mutations detected in our study were
also glycine substitutions. They are very frequent mutations
in collagen genes. As they create a kink in the folding of the
triple helix, they are assumed to be pathogenic. We found this
kind of substitution in 75% (9/12) of mutations of gene
Table 2 | Mutations in COL4A4 gene identified in 10 patients with isolated hematuria and clinical diagnosis of benign familial
hematuria
GBM changes
Family Mutations Nucleotide change Exon Gender
Age
at study Hematuria Proteinuria
Age
at biopsy
Splitting/
thickening Thinning
Frameshift
IX c.3145-3150delinsC c.3145-3150delinsC 33 M 32 Yes No — — —
M 7 Yes No — — —
Splicing
XXXI c.2860+2T4G c.2860+2T4G 31 F 48 Yes No 41 No Yes
M 18 Yes No — — —
XL c.3289+1G4A c.3289+1G4A 35 M 36 Yes No — — —
F 13 Yes No — — —
Missense
LV p.G774R c.2320G4C 28 F 39 Yes No — — —
F 36 Yes No — — —
M 18 Yes No 7 No Yes
M 16 Yes No — — —
F, female; GBM, glomerular basement membrane; M, male.
Table 3 | Variants of unknown significance identified in
COL4A4 gene
Family Variants Nucleotide change Exon
XXI p.G789G c. 2367A4T 28
XXVIII p.R908W c.2722C4T 31
XXIX c.3506-8T4G c.3506-8T4G 37
XII c.4082-8G4C c.4082-8G4C 42
Table 4 | Polymorphisms in COL4A4 gene identified in the
control group of 137 healthy individuals
Varianta Nucleotide change Exon
Allele
frequency (%)
p.P482S c.1444C4T 21 50
p.G545A c.1634G4C 23 20
p.G611G c.1833T4C 25 2
c.2165-27ins A c.2165-27ins A Intron 27 3
c.2384-5 C4T 2384-5 C4T Intron 28 9
p.L1004P c.3011T4C 33 39
p.G999E c.2996G4A 33 11
p.S1102S c.3305C4G 36 1,0
p.M1327V c.3982A4G 42 64
p.V1516V c.4548A4G 47 41
p.F1644F c.4932C4T 48 38
aNovel polymorphisms are shown in bold type.
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COL4A5. Seven of them were new mutations. Kawai et al.14
described p.G466E in a Japanese patient with ATS. Substitu-
tion of glycine with arginine at codon 325 has already been
described for a change from guanine to adenine,21 whereas
we identified a change from guanine to cytosine on the first
position of the same codon.
In addition to the pathogenically important mutations in
gene COL4A5, we also detected p.G365G, p.I444S, p.P783P,
p.Q1171Q, and p.D1425D in family IX. The members of this
family clinically presented with BFH and had a mutation
demonstrated in COL4A4. In line with the opinion of other
authors,13,14 we believe that these variants are not responsible
for the pathogenesis of ATS. Furthermore, a missense
mutation p.K664N, which was found in our family XXXVIII,
has previously been described in healthy individuals, as well
as in ATS patients with other mutations in the COL4A5 gene.
It is believed that this mutation does not cause ATS, because
it leads to a change of non-conservative amino acid.13,22
A European study by Jais et al.,23 including 329 families,
reported genotype–phenotype correlations with regard to
major rearrangements and ‘small mutations’. Furthermore,
Gross et al.5 focused on the different types of mutations and
their locations on the COL4A5 gene. He also proposed that
the different effects of various mutations may be a significant
predictor of the severity of disease. They classified ATS into
three types: (1) severe type with end-stage renal disease at
approximately 20 years, caused by large rearrangements,
premature stop, frameshift, donor splice site, and mutations
involving the NC1-domain; (2) moderate-severe type with
end-stage renal disease at approximately 26 years, caused by
non-glycine XY-missense, glycine-XY mutations involving
exons 21–47; and (3) moderate type with end-stage renal
disease at around 30 years, caused by glycine-XY mutations
involving exons 1–20. Our results of genotype–phenotype
correlations (Figure 1), based on a relatively large cohort of
patients from the Slovenian population of only 2 million, are
generally in accordance with the classification proposed by
Gross et al.5 Among exceptions, the p.G624D mutation
already discussed, which is located in the non-collagenous
domain and according to the Gross proposal could be
responsible for a moderate-severe type of ATS, should be
highlighted. In our study, it was found in families with mild
disease. Furthermore, certain aberrations in genotype–
phenotype correlation in our study could be ascribed to the
inclusion of children (4–15 years) and female patients, who
fulfilled only two clinical criteria for ATS and did not exhibit
renal failure during the observation period.
A European study by Jais et al.24 correlating genotype–-
phenotype in female subjects suggested a large intrafamiliar
heterogeneity in girls and women, thus making it impossible
to predict the renal course from genetic studies. Our findings
were in accordance with this study, especially in families III
and LIV, in which female patients showed significant
differences in the clinical course, presumably because of the
influence of random X-chromosomal inactivation.24
COL4A3 and COL4A4 gene mutations have been found to
be involved in the pathogenesis of autosomal-recessive and
autosomal-dominant ATS, as well as of thin basement
membrane nephropathy, with a high clinical variability.25,26
In our study, in addition to polymorphisms, we identified 11
changes in the COL4A3 and COL4A4 genes, of which we
believe only seven to be pathogenic. These are as follows: in
COL4A3, two glycine substitutions (p.G487C, p.G1015E) and
an insertion of three nucleotides (c.3547_3548insGGA) and
in COL4A4, a glycine substitution (p.G774R), a frameshift
(c.3145-3150delinsC), and two splice site mutations
(c.2860þ 2T4G, c.3289þ 1G4A). All of them were in a
heterozygous state and were found only in patients with a
clinical diagnosis of BFH. The findings are in agreement with
the suggestion that heterozygous carriers with a mutation in
one COL4A3 or COL4A4 allele would develop hematuria
with thin basement membrane nephropathy and a good renal
prognosis, whereas homozygous patients would present with
Table 5 | Mutations in COL4A3 gene identified in patients with isolated hematuria and clinical diagnosis of benign familial
hematuria
GBM changes
Family Mutations
Nucleotide
change Exon Gender
Age at
study Hematuria Proteinuria
Age at
biopsy Splitting/thickening Thinning
XXXII p.G487C G4T at 1459 23 M 38 Yes No — — —
F 13 Yes No — — —
XVII p.G1015E G4A at 3044 36 F 36 Yes No — — —
F 20 Yes No — — —
F 16 Yes No — — —
IV 3547-3548insGGA 3547-3548insGGA 41 F 56 Yes No — — —
F, female; GBM, glomerular basement membrane; M, male.
Table 6 | Polymorphisms in COL4A3 gene identified in the
control group of 137 healthy individuals
Variant Nucleotide change Exon
Allele
frequency (%)
p.G43R c.137G4C 2 4
p.P141L c.422C4T 7 13
p.E162G c.485A4G 9 16
p.D326Y c.976G4T 17 40
p.L399L c.1195T4C 21 54
p.H451R c.1352A4G 22 9
p.G484G c.1452G4A 23 8
p.P574L c.1721C4T 25 37
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autosomal-recessive ATS.8,27 However, in our study we did
not find any family with autosomal form of ATS. Four other
variants of an unclear pathogenetic role were detected in
COL4A3 and COL4A4 genes in our families clinically
diagnosed with BFH, but not in the control group of 137
healthy individuals. A silent mutation p.G789G may affect
splicing at the donor signal within exon 28. A missense
mutation p.R908W alters arginine, not generally conserved
amino acid in the collagenous domain and is not believed to
be a causative mutation in thin basement membrane disease.
Furthermore, we found 11 polymorphisms in the COL4A4
gene and nine polymorphisms in the COL4A3 gene, which
are partly shared with other populations.10,11,27–30
Altogether, we found pathogenic mutations in COL4A3
and COL4A4 in seven out of 40 families with BFH (18%) and
in no ATS family, which is similar to the studies by Wang
et al.29 and Buzza et al.,31 who reported a rate of 35%. The
low detection rate may be due to rather permissive inclusion
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Figure 1 | Pedigrees of affected families with COL4A5 mutations. Arrows indicate the tested individuals. Open squares are males and
open circles are females. Clinical phenotypes relevant to Alport syndrome are indicated as summarized in the key. ESRD, end-stage
renal disease; CRF, chronic renal failure.
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criteria for BFH patients with asymptomatic isolated
glomerular microhematuria and a positive family history.
In five families, a renal biopsy was performed and thin
basement membrane disease was demonstrated by electron
microscopy in all of them. However, the relatively invasive
renal biopsy is usually omitted because of the benign nature
of the disease and it has been suggested that it should be
performed only in patients with prolonged microhematuria
and impairment of renal function, and in patients with
accompanying proteinuria.32–34 It should be stressed that
some other renal diseases can also manifest as isolated
hematuria and, on the other hand, some other genes might
be involved in the pathogenesis of BFH.
In spite of the large size and complexity of the COL4A3,
COL4A4, and COL4A5 genes, we optimized non-isotopic
SSCP so that enabled us to analyze up to three exons with at
least 270 samples in a single run. The overall detection rate of
mutations in COL4A3, COL4A4, and COL4A5 in our study
was 40%. A possible explanation of such a rate was the
presence of mutations in the non-coding parts of the collagen
genes35 and the involvement of other genes in the pathogen-
esis of familial hematuric syndromes. SSCP proved to be a
sensitive method in relation to the number of polymorphi-
sms and mutations found, in addition to having a relatively
high throughput, and was a cost effective, simple, efficient,
and suitable method for large-scale mutation screening and
diagnostics of large genes such as type IV collagen genes.
In conclusion, 16 novel mutations were identified by
screening all three COL4 genes with our optimized SSCP, in
patients with a diagnosis of ATS or BFH. Our study therefore
broadened the spectrum of mutations in COL4A3, COL4A4,
and COL4A5. Genotype–phenotype correlation enabled
better understanding of different types of mutations that
have resulted in various phenotypes of ATS. An interesting
finding of our study was missense mutation p.G624D of
COL4A5, demonstrated in six families, of which five
appeared clinically to present with BFH. Molecular genetic
data have important implications in the diagnosis, prognosis,
and genetic counselling of familial hematuric syndromes,
particularly in asymptomatic female carriers and children.
The detection of a mutation in affected family members is
also important for prenatal diagnosis and subsequent
diagnostics of their offspring and could therefore reduce
the need for more invasive renal biopsy.
MATERIALS AND METHODS
Patients
One hundred and forty-one patients from 57 unrelated families with
suspected ATS or BFH, registered at several nephrology centers in
Slovenia, a country with a population of 2 millions, were included in
the study.
Fifty-one patients (30 female and 21 male, age range from 10
months to 50 years) from 17 families fulfilled at least two of the
diagnostic criteria for ATS:36 a positive family history of hematuria
with or without renal failure, high-tone neurosensory deafness,
diagnostic ophthalmologic signs, and typical electron microscopy
abnormalities of the GBM. Renal biopsies were obtained from 26
patients and processed for standard light, electron, and immuno-
fluorescence microscopy. Thinning, characteristically pronounced
thickening, and multilamellation of the GBM were found by
electron microscopy. Moreover, light microscopy histologic changes
and immunofluorescence findings were compatible with the
diagnosis of ATS. Hearing loss was present in 12 patients from
seven families and ocular lesions (lenticonus and/or maculopathy)
were identified in 15 patients from six families.
Furthermore, 90 patients (49 female and 41 male, age range from
5 to 52 years) from 40 families were suspected by nephrologists of
having BFH. All of these 90 patients had persistent isolated
hematuria with dysmorphic red blood cells in urine observed by
phase-contrast microscopy, occasionally associated with proteinuria
in traces, normal renal function, normal blood pressure, negative
urine culture, and normal calciuria. Hematuria persisted for more
than 6 months in all these subjects. Renal biopsy was performed in
seven patients from seven families and diffuse prominent thinning
of the GBM was demonstrated by electron microscopy.
The control group consisted of 137 healthy blood donors with no
evidence of ATS or BFH.
The study was approved by the Slovenian Medical Ethics
Committee.
PCR-SSCP
Genomic DNA was isolated from peripheral blood lymphocytes, and
PCR amplification was performed in a total volume of 12 ml, using
30 ng of DNA, 3 pmol of each primer, 3 or 1.5 mM MgCl2 (Applied
Biosystems, USA), 10PCR buffer (Applied Biosystems, Foster
City, CA, USA), 8 nmol of deoxyribonucleotide triphosphates
(Applied Biosystems), and 0.25 U of Ampli Taq GoldTM polymerase
(Applied Biosystems). Intronic primers and PCR conditions for
COL4A3 were as described by Heidet et al.,28 for COL4A4 by Boye
et al.,27 and for COL4A5 were as by Renieri et al.12 All exons of the
COL4A3, COL4A4, and COL4A5 genes were screened for mutations.
Screening for mutations was performed by non-isotopic high-
resolution single-stranded conformation analysis. Large glass plates
(approximately 35 40 cm) were used in order to obtain maximum
sensitivity. The shorter plate was coated with Repel-Silane (2%
dichlorodimethylsilane in 1,1,1-trichloroethane). The longer plate
was coated with Bind-Silane (20 ml of g-methacryloxypropyl-
trimethoxysilane, 5 ml of bidistilled H2O, 5 ml of EtOH), then
warmed to 501C for about 30 min and cooled to room temperature.
A3–4 ml portion of 12 ml PCR product was mixed with 10 ml of
loading buffer (95% formamide, 5 mM NaOH, 0.1% bromophenol
blue, and 0.1% xylene cyanol). Samples were heated to 951C for
2 min and then cooled in ice water. A 3–4 ml portion of each sample
were loaded onto polyacrylamide gels (35 40 0.04 cm). Combs
with 96 teeth were used for loading samples. Ten percent acrylamide
gels with 2.6% bis-acrylamide were used to analyze multiple exons
(up to three at once) so that at least 270 samples could be analyzed
at a time. Gels were run at 41C in 1TBE (50 mM Tris-borate,
pH 8.3, 4 mM ethylenediaminetetraacetic acid).
For DNA visualization, we used the optimized method of
Heukeshoven and Dernick37 with most phases at 551C. Silver
staining was performed on thin gels (0.4 mm) fixed on the larger
glass plate.
Sequencing
DNA samples showing mobility shift in SSCP were sequenced. PCR
products were purified using a QIAquick spin purification kit
(Qiagen, Chatsworth, CA, USA) and automatically sequenced using
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a BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied
Biosystems) on an ABI Prism 310 (Applied Biosystems).
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